Abstract: A polyether dendrimer of formula (I), wherein the symbols and indices have the following meanings: each Y is independently [R1—(O—CH2—CH2)p—O—]; each Z is independently [R2—(O—CH2—CH2)q(O—CH(CH3)—CH2)r—O—]; each R1 is independently H, CH3 or C2-C4-alkyl; each R2 is independently linear or branched C8-C22-alkyl; X is H or C1-C4-alkyl; m is 1, 2, 3, 4, 5 or 6; n, o are rational positive numbers >0, with the proviso that the sum of n and o is 2m; p is a natural number from 5 to 50; q is a natural number from 1 to 50; r is 0 or is a natural number from 1 to 30, with the proviso that 5?q+r?50, and ˜ denotes the bonding of the respective group to the dendron scaffold, is useful for solubilizing sparingly-water soluble active ingredients, in particular pesticides.

Abstract: The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

Abstract: The present invention provides the efficacy-enhancing agent composition for an agricultural chemical containing at least one compound (A) selected from specific ethoxylate compounds, specific polyoxyethylene fatty acid esters, specific polyoxyethylene sorbitan fatty acid esters, specific (poly)glycerol fatty acid esters, and specific alkyl saccharides; and at least one compound (B) selected from specific polyoxyalkylene alkyl ethers and specific aliphatic alcohols.

Abstract: The present application provides a pharmaceutical formulation comprising a folate receptor (FR)-targeting antineoplastic substance or composition, wherein the pharmaceutical formulation is configured for administration by inhalation, wherein the FR-targeting antineoplastic substance or composition is comprised in a nanoparticle and wherein the nanoparticles are comprised in microparticles, and its use in the treatment of a proliferative disease affecting at least part of the respiratory tract. The present application further provides a pharmaceutical formulation comprising an antineoplastic agent and a FR-targeting excipient, for use in the treatment of a proliferative disease affecting at least part of the respiratory tract.

Abstract: The present invention relates to the use of compounds of the formula (I) for the care, preservation or improvement of the general condition or appearance of the skin or hair, and to preparations comprising compounds of the formula (I).

Abstract: Compositions and methods for repair of tissue defects are disclosed. The compositions are prepared by entangling high molecular weight polycaprolactone polymer molecules with a polysaccharide such as hyaluronic acid by a dual solvent emulsion process to produce a porous flexible matrix which supports cell and tissue growth in vivo and ex vivo.

Abstract: The invention is concerned with the compounds of formula I: and salts thereof and other compounds of formulas II-IX as disclosed herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formulas I-IX as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain or asthma.

Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.

Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.

Abstract: The present invention generally relates to non-aqueous solutions of plant growth regulator(s) and polar and/or semi-polar organic solvent(s), methods for making said non-aqueous solution, and methods for improving the growth and crop productivity of plants using said non-aqueous solution.

Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin.

Abstract: The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.

Abstract: Novel methods for treating or reducing the likelihood of acquiring vaginal dysfunctions, more particularly vaginal dryness and dyspareunia, leading to sexual dysfunction and low sexual desire and performance, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor. Further administration of estrogen or selective estrogen receptor modulator, particularly those selected from the group consisting of Raloxifene, Arzoxifene, Tamoxifen, Droloxifene, Toremifene, Iodoxifene, GW 5638, TSE-424, ERA-923, and lasofoxifene, and more particularly compounds having the general structure: is specifically disclosed for the medical treatment and/or inhibition of development of some of these above-mentioned diseases. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.

Abstract: Disclosed herein are compounds that selectively inhibit members of the PTP family of enzymes. Synthesized compounds demonstrated selective inhibition of TC-PTP. Also provided are methods of using the compounds and formulations containing the compounds. Also described is a fluorescence-tagged combinatorial library synthesis and screening method. And methods of using these compounds to effect enzyme activity both in cells and in vitro as well as method of using these compounds to treat diseases in human and animals.

Abstract: Provided herein is a combination therapy comprising an mTOR inhibitor and a JAK inhibitor. The combination therapy is useful for the treatment of a variety of cancers, including myeloproliferative neoplasms. The combination therapy is also useful for the treatment of any number of JAK-associated diseases.

Abstract: The present invention relates to a method for preparing granules comprising the steps of A) preparing an adjuvanted slurry by milling an aqueous composition Al containing a pesticide and a silica absorbent to yield a pesticidal slurry, and adding an adjuvant to the pesticidal slurry; and B) granulating the adjuvanted slurry, wherein the granulation comprises a fluidized bed granulation or sprouted bed granulation.

Abstract: Methods of treating orthostatic hypotension are disclosed. The methods include administering to a subject in need thereof an effective amount of a beta 2 (?2) adrenoceptor antagonist, and in particular, the specific ?2 adrenoceptor antagonist, 3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]butan-2-ol.

Abstract: The present invention relates to a method for a preparation of a solid composition comprising the steps of a) dissolving a premix in a premix-solvent, or melting a premix, wherein the premix contains a pesticide and a nonionic, amphiphilic polyalkoxylate, b) solidifying the premix by removing the premix-solvent, or by cooling, and c) contacting the premix with at least one auxiliary. The invention further relates to a solid composition obtainable by said method; to a method for the preparation of an aqueous tank mix, in which a pesticide is present as suspended particles having a particle size below 1.

Abstract: The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof. Also described is a liquid pharmaceutical composition according to the invention for use in the treatment of the human or animal body.

Abstract: The invention relates to agents for the control of parasites on animals, comprising an active substance from the group of the phenylpyrazoles and vitamin E or a derivative thereof, such as particularly vitamin E acetate, as well as optionally a further active substance from the group of the pyrethroids and/or optionally additionally further active and/or auxiliary substances. In particular, the invention relates to the use of such agents for the control of ectoparasites such as, in particular, fleas, ticks and sand flies in pets such as, in particular, in dogs, cats and ferrets.